Editorial: Advances in the treatment of chronic myeloid leukemia

Ahmet Emre Eşkazan; Chung H Kok; David Yeung; Jignesh Dalal; Mario Tiribelli

doi:10.3389/fonc.2023.1166588

Editorial: Advances in the treatment of chronic myeloid leukemia

Front Oncol. 2023 Mar 9:13:1166588. doi: 10.3389/fonc.2023.1166588. eCollection 2023.

Authors

Ahmet Emre Eşkazan¹, Chung H Kok^{2

3

4}, David Yeung^{2

3

4

5}, Jignesh Dalal^{6

7}, Mario Tiribelli^{8

9}

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
² Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
³ Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
⁴ Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia.
⁵ Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia.
⁶ Division of Hematology and Bone Marrow Transplant, Rainbow Babies and Children's Hospital, OH, United States.
⁷ Case Western Reserve University, Cleveland, OH, United States.
⁸ Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) - Udine Hospital, Udine, Italy.
⁹ Department of Medicine, University of Udine, Udine, Italy.

No abstract available

Keywords: BCR::ABL1 transcript; COVID-19; adverse event; arterial occlusive event; quality of life; stem cell transplantation; treatment-free remission; tyrosine kinase inhibitor.

Publication types

Editorial